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because of misdiagnosis, late presentation or spontaneous reperfusion. Man-
agement of STEMI has evolved considerably worldwide during the past two
decades.
Aim: To describe the change over time of reperfusion strategy in STEMI
pts among the population of MIRAMI registry. 
Methods: A total of 1318 pts admitted for AMI between January 1995 and
December 2010 were included in our MIRAMI (MonastIR Acute Myocardial
Infarction) registry. We evaluated the change over time of each treatment
strategy during the mentioned study 
The proportion of pts receiving a reperfusion therapy was fluctuating but
relatively stable during the last 16 years ranging from 45.2% in 1995 to 58.2%
in 2010 with a peak of 74.2% in 2001. From 1995 to 2000, reperfusion was
almost exclusively performed by thrombolysis whereas a dramatic increase of
the use of PAMI was observed between 2000 and 2005 followed by a decrease
in favor of the use of thrombolysis during the following 5 years probably due
to an increase of the use of prehospital thrombolysis that ranged from14.3%
in 2001 to 84% in 2009 among the thrombolysed pts. 
Conclusion: In our MIRAMI Registry, the rate of reperfusion therapy was
relatively stable over the 16 year-period of the study. Over all, thrombolysis
was more frequently used than angioplasty except for the period between 2000
and 2005. The most frequently recent use of thrombolysis over angioplasty
was presumably due to an increase of its use in the ambulance. 
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Background: The standard of care for ST-segment elevation myocardial
infarction (STEMI) is prompt coronary reperfusion with primary percutaneous
coronary intervention or thrombolysis .
However, a substantial number of patients (pts) with myocardial infarction
receive only conservative medical management.
The aim of the present study was to examine predictive factors of not
receiving reperfusion therapy among STEMI pts.
Methods and Results: From January 1995 to December 2010, the
MIRAMI Registry enrolled 1318 patients admitted for STEMI. Multivariate
analysis was performed to determine predictors of not receiving reperfusion
therapy. Two hundred eighty nine patients were excluded from this analysis
because of lacking data. The remaining 1029 pts were considered for this anal-
ysis with 360 (35%) that received a reperfusion therapy and 669 (56%) that
were treated conservatively. Multivariate analysis identified only three inde-
pendent predictors for not receiving a reperfusion therapy: age 75 years
(p=0.004), time to hospital admission -6 hours from the onset of symptoms
(p<0.001) and night (from 08:00 PM to 08:00 AM) occurrence (p=0.004).
Conclusions: More than half of the population of this study did not receive
a reperfusion therapy. Elderly, female patients, late presenters and patients
who present at night are more likely to not receive a reperfusion therapy. 
Results:
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Objectives and background: Specific data about clopidogrel response in
elderly patients are lacking. The present study was performed to compare platelet
reactivity and clopidogrel response between elderly patients (> 75 yrs) and
younger patients (< 75 yrs) undergoing Percutaneous Coronary Intervention (PCI)
for Non ST segment Elevation Acute Coronary Syndrome (NSTE ACS). 
Methods: 689 patients were enrolled, including 162 elderly and 527
younger patients. All patients received loading dose of 600 mg of clopidogrel
followed by 150 mg daily. Post-treatment platelet reactivity was assessed by
ADP 10 μmol/L-induced platelet aggregation (ADP-Ag) and specific pharma-
cological response to clopidogrel by the Platelet Reactivity Index VASP (PRI
VASP). High Post-treatment platelet Reactivity (HPR) was defined as ADP-
Ag >70%. Clinical events were recorded during one month Follow-Up (FU).
Results: Elderly patients had a higher rate of both ischemic and bleeding
complications (p=0.04 and 0.03 respectively). Post-treatment platelet reac-
tivity in response to both loading and maintenance clopidogrel doses was
higher in elderly than in younger patients: 50±17% vs. 45±17%, p=0.002; and
57±15% vs. 53±16%, p=0.0005, respectively. The rate of HPR was signifi-
cantly higher in elderly patients after 600 mg and 150 mg: 14% vs. 9%,
p=0.04; and 23% vs. 15%, p=0.02, respectively. Conversely, pharmacological
response to clopidogrel was not impaired in elderly patients after loading and
maintenance doses: 43±21% vs. 46±21%, p=0.17 and 38±18% vs. 39±18,
p=0.55, respectively. 
Conclusion: Elderly patients have an impaired prognosis after ACS. They dis-
play higher post-treatment platelet reactivity. However, this higher platelet reac-
tivity does not seem to be related to impaired specific response to clopidogrel.
049
Invasive detection of myocardial microvascular disease in patients
with end stage renal disease. The MICROCARD study
Denis Angoulvant [Orateur] (1), Cyrille Bergerot (2), Aline Mézergues
(3), Xavier André-Fouët (1), Theodora Bejan-Angoulvant (4)
(1) Groupement Hospitalier Est – Hôpital Cardiologique, Cardiologie D,
Lyon Cedex 03, France – (2) Groupement Hospitalier Est – Hôpital Car-
diologique, Explorations Fonctionnelles, Lyon, France – (3) CIC PAM
CPMH – Réseau MONICARD – Hôpital Cardiologique, Lyon, France –
(4) Inserm, CIC 201 Hospices Civils de Lyon, Lyon, France
Cardiovascular diseases are the leading cause of mortality in patients with
end stage renal disease (ESRD). A positive non invasive test for myocardial
P CI
Age 0.004 0.973-0.995
Hospital admission=6 hours <0.001 0.066-0.187
Night occurrence 0.004 0.236-0.766
Female sex 0.059 0.49-1.01
Serum creatinin=150 μmol/l 0.936 0.62-1.66
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ischemia is frequent in ESRD patients and is a major predictor of mortality.
Interestingly the incidence of significant coronary stenosis (>70%) is low
when coronary angiography is performed suggesting other mechanisms such
as myocardial microvascular disease (MMD).
We are conducting a prospective observational study (NCT01291771)
evaluating the incidence of major adverse cardiac events (MACE) in ESRD
patients with proven MMD and no history of coronary disease. 105 patients
with positive test for myocardial ischemia will be explored by coronary angi-
ography. Detection of MMD will be performed simultaneously with a pressure
sensor/thermistor-tipped guidewire in the left anterior descending (LAD), the
left circumflex (LCX) and the right coronary artery (RCA). We will measure
Fractional Flow Reserve (FFR) and Coronary Flow Reserve (CFR) allowing
calculation of the Index of Microcirculatory Resistance (IMR). These patients
will be compared in a 2 years follow-up for the incidence of MACE with 105
ESRD patients without myocardial ischemia on non invasive testing. 
We are reporting the preliminary data of patients (n=6) in whom invasive
MMD evaluation was performed. Mean age 63±8 years, sex ratio=1, diabetic
nephropathy=1, under dialysis=4. 1 patient had significant coronary stenosis,
the others had normal angiograms (32%) or non-significant coronary atheroma
(50%). In patients without significant coronary stenosis, mean FFR was
0.93±0.02 (LAD), 0.98±0.02 (LCX) and 0.95±0.02 (RCA). Mean CFR was
3.3±2.7 (LAD), 2.3±1.1 (LCX) and 3.1±1.4 (RCA). Mean IMR was 19±6
(LAD), 27±15 (LCX) and 30±26 (RCA).
Preliminary data suggest impaired myocardial microvascular function in
ESRD patients with positive test for myocardial ischemia and non significant
coronary artery stenosis.
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Objectives: The aim of this investigation was to test the diagnostic addi-
tive value of the C-Terminal Provasopressin (Copeptin) an indirect marker for
arginin-vasopressin (AVP) in the detection of STEMI patients presenting early
(<6 hours after the Symptom Onset (SO). 
Methods: We measured plasma copeptin in 464 consecutive STEMI
patients (78% men, mean age 63 ± 14 years) immediately after the sheath
insertion and before the primary PCI. Of those patients 200 (43.1%) had a
blood sampling early after SO (<6 hours) and were included in this analysis.
Using the previously established threshold of 4.8pmol/L for copeptin and the
local 99th of the upper limit of the normal value for troponin I (0.15μg/L) we
evaluated the additive value of the combination of copeptin and troponin I in
this AMI patients. 
Results: In the 200 Early STEMI presenters, the median time between SO
and blood sample was 165 minutes; IQR [125-230], (min 35-max 360). The
median value of Troponin I at sheath insertion was 0.59 μg/L; IQR [0.13-3.2]
and 33.1 pmol/L, IQR [11.6-111] for copeptin. Troponin I was negative at
admission in n=56 (28%) STEMI patients and copeptin was negative at admis-
sion in n=54 (27%) STEMI patients. Patients with one or two negative bio-
markers presented earlier than those with both positive biomarker (median
time in minutes 152 [127-218] vs. 180 [125-240]). Among the n=56 patients
with a negative troponin value at admission, n=38 (67.8%) had a positive
copeptin value (>4.8pmol/L).
Therefore, when copeptin is combined to troponin I, the proportion of
STEMI patients non-detected was reduced from 28% to a remaining 9.2%
(p<0.001) of very early presenters (median time of 145 min IQR [116-180]).
Conclusions: The combination of copeptin and troponin improves the
diagnostic value in AMI patients but cannot rule out the diagnosis of acute
STEMI in very early presenters (<3 hours).
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Introduction: Paraoxonases (PONs) are closely related antioxidant
enzymes encoded by clustered genes on chromosome 7q. Two particular poly-
morphisms, namely PON1-192 and PON2-311, in the genes encoding the anti-
oxidant enzymes paraoxonase-1 (PON1) and paraoxonase-2 (PON2) have
been associated with an increased risk of acute myocardial infarction (AMI).
However, previous findings have been contradictory. We evaluated three PON
polymorphisms (PON1 Leu55Met and Gln192Arg; PON2 Ser311Cys) in
Tunisian patients with AMI.
Methods: 168 AMI patients compared to 169 healthy volunteers.
Results: PONs allele and genotype frequencies did not differ between
patients and controls. 
The PON polymorphisms (PON1 Leu55Met and Gln192Arg; PON2
Ser311Cys) were not significantly associated with AMI (p=1.11, p=0.09,
p=1.46 respectively). No significant differences in age, sex, BMI, waist cir-
cumference, total Cholesterol, HDL-C and LDL-C were detected among the
three-genotype subgroups of PON1 Leu55Met, PON1 Gln192Arg and PON2
Ser311Cys in the AMI patients.
Conclusions: The PON1 Leu55Met, PON1 Gln192Arg and PON2 Ser311Cys
polymorphisms are not related to acute myocardial infarction in Tunisian population
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Background and aim: Fourier domain Optical Coherence Tomography
(FD-OCT) is a new imaging modality characterized by a high axial resolution
Usefulness of Copeptin in AMI 
